Influence of age, body mass index and family income on the health Quality of Life among the breast cancer patients in Bangladesh: a cross-sectional study - Report - MDSpire
Advertisement
Influence of age, body mass index and family income on the health Quality of Life among the breast cancer patients in Bangladesh: a cross-sectional study
Clinical Report: Impact of Age, BMI, and Socioeconomic Status on QoL in Breast Cancer Patients
Overview
This study examines the effects of age, body mass index (BMI), and socioeconomic status on the quality of life (QoL) of breast cancer patients in Bangladesh.
Background
Breast cancer is a leading cause of cancer incidence among women globally, with increasing rates in low- and middle-income countries, including Bangladesh. Understanding the factors influencing QoL in breast cancer patients is crucial.
Data Highlights
Variable
Mean (SD)
Age
49.5 (9.02)
Global Health Score
42.44 (12.46)
Overweight Patients
52.5%
Stage II Cancer
53%
Mastectomy
58.5%
Chemotherapy
98%
Key Findings
Older age is associated with a lower global health score (b2 = 0.68; p < 0.001).
Higher family income correlates with better QoL.
Lower family income is associated with increased financial difficulties.
BMI has limited associations with QoL.
Insomnia and dyspnea scores are significantly higher in older patients.
Clinical Implications
Healthcare providers should consider age and socioeconomic factors when assessing QoL in breast cancer patients. Addressing financial difficulties may improve patient outcomes and overall QoL.
Conclusion
The study highlights the impact of age and socioeconomic status on the QoL of breast cancer patients in Bangladesh.
Harold Burstein, MD, PhD, and Erica Mayer, MD, MPH discuss results from the TRAK-ER trial, which were presented at the 2026 ESMO Breast Cancer Congress.
Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients with early breast cancer.
Harold Burstein, MD, PhD, and Ana C. Garrido-Castro, MD discuss results from the Pumitamig + DB-1305/BNT325 trial, which were presented at the 2026 ESMO Breast Cancer Congress.
